GlobeNewsWire
02 Jun 2026, 13:45 UTC · 16w ago
Verdict
Headline takes no side. We score MAIA +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 70% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
MAIA Biotechnology CEO Vlad Vitoc and Director Stan V. Smith purchased a combined total of approximately 147,700 shares of common stock on the open market.
More positive than 92% of claims this week
The company is advancing its lead drug candidate, ateganosine, toward later-stage development for the treatment of advanced non-small cell lung cancer.
Continue reading
5 related stories
GlobeNewsWire
51m ago
GlobeNewsWire
51m ago
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 76% of claims this week
Directors and officers currently hold a cumulative 20.46% stake in the company.
More positive than 48% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
The CEO and a Director increased their ownership positions through open market purchases, signaling strong internal confidence in the company's drug platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+2.7%
Price agrees with the score
$1.33 vs $1.30 close before publication (Jun 1) · not market-adjusted
MAIA chart →
